Effects of Pharmacological GIP Infusion on Insulin, Glucagon, and Cardiovascular Responses During Hyperglycemia in Type 2 Diabetes
Abstract
The pharmacological actions of glucose-dependent insulinotropic polypeptide (GIP) in type 2 diabetes (T2D) remain incompletely defined. We evaluated the acute effects of intravenous GIP infusion at a pharmacological dose on glucose homeostasis and cardiovascular responses during hyperglycemia in individuals with T2D. Ten participants, whose T2D was managed by diet and/or metformin monotherapy (n = 4 men and 6 women; mean ± SEM age 68.2 ± 3.4 years, BMI 31.7 ± 1.2 kg/m2, HbA1c 6.9% ± 0.6%), were studied on two occasions in a double-blind, randomized, crossover design. During each study visit, hyperglycemia (∼15 mmol/L) was maintained for 210 min by variable intravenous (IV) glucose infusion, and GIP(1-42) (4 pmol/kg/min) or 0.9% saline was infused IV. Plasma insulin, C-peptide, glucagon, glucose infusion requirements, mean glucose/insulin ratio (M/I ratio; a surrogate for insulin sensitivity), heart rate, and blood pressure were assessed. GIP increased baseline-subtracted insulin and C-peptide responses between 0 and 210 min (mean ± SEM 8,717 ± 1,827 vs. 3,074 ± 698 mU/L*min, P = 0.003; and 383.1 ± 58.9 vs. 185.0 ± 35.0 nmol/L*min, P = 0.0005, respectively) and increased glucose infusion requirements to maintain hyperglycemia (mean ± SEM 6.1 ± 0.6 vs. 4.9 ± 0.4 mg/kg/min; P = 0.02), but attenuated glucagon suppression (P = 0.03) and reduced the M/I ratio (P < 0.0001). GIP also increased heart rate and reduced systolic and diastolic blood pressures (P < 0.01 each). These…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 6 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.